Muhyiddin announced on Tuesday June 15 that the nation's Covid-19 recovery plan would move into the second phase once cases drop below 4, 000 and about 10% of the population is fully vaccinated. So far, 19 Pikas vaccine dispensing centres PPV have started operations in Kuala Lumpur, Putrajaya, Selangor, Johor, Melaka, Negri Sembilan, Perak, Kedah, Penang and Terengganu.Next
PUTRAJAYA: Over 100,000 workers in the manufacturing sector have received their first Covid-19 vaccination dose under the Public-Private Partnership Covid-19 Industry Immunisation Programme Pikas.
The Pikas programme was also launched for critical manufacturing sub-sectors in Johor, Penang and Sarawak. Preclinical studies have demonstrated that PIKA recombinant COVID-19 vaccine is capable of inducing rapid and efficient production of neutralizing antibody and cellular immunity against the currently prevalent virus variants of SARS-CoV-2, including the alpha, beta, gamma and delta variants from the United Kingdom, South Africa, Brazil and India. As part of our commercialization strategy, we are about to finish the construction of a state-of-art manufacturing facility with annual production capacity of up to one billion doses to meet the future need of mass immunization.
YishengBio's other product candidates also include PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001, and PIKA YS-HBV-001, PIKA YS-HBV-002, PIKA YS-ON-002 and PIKA influenza vaccine.
Preclinical studies have demonstrated that it has the potential to become a universal prophylactic and therapeutic vaccine against existing and emerging variants, including the alpha, beta, gamma and delta variants from the United Kingdom, South Africa, Brazil and India. Texas Instruments set up an in-house vaccination facility to vaccinate 2,371 of its workers. We appreciate the unified and swift steps taken by various healthcare authorities and collaborators in moving this program into clinical stage.Next
Launched on June 16, Pikas is a strategic collaboration between the public and private sectors that focuses on vaccinating workers in the manufacturing sector.
NZCR investigates potential new medicines for the global pharmaceutical and biotechnology industry and other research organizations.Next
The merger of these highly respected, world-renowned early phase clinical research units will ensure New Zealand is a stronger player in the global clinical research industry.
At present, he said the Pikas pilot project would involve some 150,000 doses. The positive list of companies allowed to operate during Phase One of the plan will be extended to Phase Two. Muhyiddin said the pace of Pikas is expected to pick up in the coming months due to better supply of Covid-19 vaccines.Next
YishengBio is headquartered in Beijing with more than 600 employees in China, U.
YishengBio is a biopharmaceutical company focusing on discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics in the field of infectious diseases and cancer. Once completing necessary clinical studies, YishengBio is to seek emergency use authorization "EUA" and approval to market PIKA recombinant COVID-19 vaccine in multiple countries. More than 500 companies with a total of 106,591 workers have applied to participate in the Pikas programme..Next
The PIKA immunomodulating technology platform is developed in-house through which it empowered and nurtured a diverse pipeline of vaccines and therapeutic biologics with better efficacy and safety potential to address the unmet medical needs in infectious disease and cancer fields.